Forty patients with chronic active hepatopathy- or hepatic cirrhosis were randomly treated with arginine thiazolidinecarboxlyate (ATCA) or placebo, administered by intravenous infusion through phleboclysis. Tests for revealing the effects of the drug on liver function or liver damage were carried out. Comparison of the values of transaminases, alkaline phosphatase, total bilirubinaemia and aromatic amino acids at the end of treatment, showed significantly lower levels in the ATCA-treated patients than the placebo group. No local or general intolerance reactions, ascribable to the ATCA were observed. © 1981.
Effect of arginine thiazolidinecarboxylate (ATCA)* * SULFILE is the trade name for arginine thiazolidinecarboxylate (200 mg vials) manufactured by Poli-Industria Chimica, Italy. on some clinical and functional parameters in cirrhotic patients
Zoli, G.
;
1981
Abstract
Forty patients with chronic active hepatopathy- or hepatic cirrhosis were randomly treated with arginine thiazolidinecarboxlyate (ATCA) or placebo, administered by intravenous infusion through phleboclysis. Tests for revealing the effects of the drug on liver function or liver damage were carried out. Comparison of the values of transaminases, alkaline phosphatase, total bilirubinaemia and aromatic amino acids at the end of treatment, showed significantly lower levels in the ATCA-treated patients than the placebo group. No local or general intolerance reactions, ascribable to the ATCA were observed. © 1981.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
